Ivar Sønbø Kristiansen, professor em. ved Universitetet i Oslo og assosiert partner i Oslo Economics, ble tildelt The Career Achievement Award for sitt betydelige bidrag innen feltet medisinsk beslutningstaking.
Ivar Sønbø Kristiansen, professor em. ved Universitetet i Oslo og assosiert partner i Oslo Economics, ble tildelt The Career Achievement Award for sitt betydelige bidrag innen feltet medisinsk beslutningstaking.
Pasienter med inflammatorisk revmatisk leddsykdom anbefales å trene kondisjon og styrke viser en ny studie som er gjennomført av forskere hos NKRR ved Diakonhjemmet Sykehus.
At the ninth annual Symposium on Clinical Interventional Oncology, professor Daniel Sze (Stanford University, USA) noted in his speak that immunotherapy is a “huge opportunity” for interventional oncology.
New immunotherapy drugs, which work by stimulating the body's own immune system to attack cancer cells, described by many as the greatest thing that has happened in the cancer field in the past decade. Yet no treatment without side effects, and as the use of new drugs increases so does also reports of serious side effects.
Immunotherapy is described as the future treatment of cancer. The gentle treatment is based on the body's own immune system to fight cancer. In Norway, immunotherapy treatment using the medicines Nivolumab and Pembrolizumab is approved for use in patients with melanoma.
Immunotherapy within oncology is based on the use of soluble or cell-bound components of the immune system to treat cancer. In Norway, today, different forms of immunotherapy are used to treat: Leukemia (blood cancer), lymphoma, moles, non-small cell lung cancer and kidney cancer.
Copyright © 2014 NORINnetwork .com - by IbosimSolutions Drupal